Avenue Therapeutics (NASDAQ:ATXI) Trading Down 3.4% – Should You Sell?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) shares traded down 3.4% during trading on Thursday . The company traded as low as $0.3188 and last traded at $0.3188. 130 shares were traded during trading, a decline of 98% from the average session volume of 5,622 shares. The stock had previously closed at $0.33.

Avenue Therapeutics Price Performance

The company has a market cap of $1.05 million, a PE ratio of 0.02 and a beta of -0.17. The company’s fifty day moving average price is $0.35 and its 200 day moving average price is $0.38.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.

The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.